Addex Therapeutics Ltd - American Depositary Shares (ADXN)
5.6400
-0.3600 (-6.00%)
NASDAQ· Last Trade: Jun 25th, 1:53 PM EDT
Addex Therapeutics (NASDAQ:ADXN) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below. Benzinga APIs provide real-time access to
Via Benzinga · June 25, 2026
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · September 30, 2025
Via Benzinga · September 12, 2025
Via Benzinga · September 12, 2025
Via Benzinga · September 12, 2025
Via Benzinga · September 11, 2025
Via Benzinga · September 3, 2025

Via Benzinga · October 22, 2024

Via Benzinga · October 22, 2024

Via Benzinga · September 30, 2024

Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatment. Addex could receive up to $330 million plus royalties under the agreement, while advancing its own GABAB PAM program for chronic cough.
Via Benzinga · August 27, 2024

Via Benzinga · August 27, 2024

Addex Therapeutics announces Janssen Pharmaceuticals, a Johnson & Johnson unit, has halted ADX71149 development for epilepsy after Phase 2 data.
Via Benzinga · July 22, 2024



